Future Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses closing thoughts on the results of the study and its implications for future treatment options for patients with relapsed/refractory multiple myeloma.

Pharmacy Times® interviewed Suzanne Trudel, MD, MSC, FRCPC, an associate professor at the University of Toronto and a consultant in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto, on one of her presentations at the 62nd ASH Annual Meeting and Exposition. The presentation is on the part 1 results of a dose finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).

In this video, Trudel discusses closing thoughts on the results of the study and its implications for future treatment options for patients with RRMM.

Related Videos
Patient with cancer receiving an infusion | Image credit: RFBSIP - stock.adobe.com
Burnout illustration | Image credit: Vikky Mir - stock.adobe.com
Stack of files and gavel | Image credit: BillionPhotos.com - stock.adobe.com
Public Health Matters podcast logo
Cancer patient with IV | Image credit: Monkey Business - stock.adobe.com
Capitol Building | Image credit: lazyllama - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.